The Use of Humoral Responses as a Marker of CMV Burden in HIV Patients on ART Requires Consideration of T-Cell Recovery and Persistent B-Cell Activation
Table 1
(a) Demographics of patient cohort: gender, age at commencement of ART (in years), ethnicity, CD4 T-cell counts at commencement of ART and after 1 year (cells/μL). Column 7 shows hospital records indicating detection of CMV DNA before ART (D = detected, ND = not detected, N/A = not assayed). Column 8 shows CMV serostatus using in-house ELISAs (see Section 2). (b) CMV antibody levels are higher in CMV seropositive HIV patients at 10 years after ART than controls similar in age.
(a) Characteristics of HIV patient cohort
Sex
Age
Ethnicity
CD4 T-cells/L
CMV DNA
CMV IgG
Comments
Nadir
1 year
HIV cohort
1
M
40
Caucasian
42
112
ND
Pos.
CCR5 delta 32 deletion
2
F
28
Asian
8
352
ND
Neg.
3
F
43
Aboriginal
90
378
N/A
Pos.
IRD-HSV, 1 month after ART
4
M
42
Caucasian
33
28
ND
Pos.
IRD-CMV, 7 months after ART
5
M
47
Caucasian
110
169
N/A
Pos.
6
M
43
Caucasian
4
465
ND
Neg.
7
M
56
Caucasian
9
176
D
Pos.
Oesophageal tumour before ART
8
M
45
Caucasian
70
105
ND
Pos.
Syphilis, 8 years after ART
9
M
48
Asian
18
189
ND
Pos.
IRD-uveitis, 1 month after ART
10
F
60
Caucasian
56
220
D
Pos.
HIV encephalitis, before ART
11
M
39
Caucasian
208
240
D
Pos.
CMV pneumonitis, before ART
12
M
67
Asian
14
250
ND
Pos.
Died age 76
13
F
60
Caucasian
4
108
N/A
Pos.
Died age 65, breast cancer
(b) Comparison of CMV seropositive HIV and control cohorts